179 related articles for article (PubMed ID: 28591789)
1. Vancomycin Taper and Pulse Regimen With Careful Follow-up for Patients With Recurrent Clostridium difficile Infection.
Sirbu BD; Soriano MM; Manzo C; Lum J; Gerding DN; Johnson S
Clin Infect Dis; 2017 Oct; 65(8):1396-1399. PubMed ID: 28591789
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Oral Vancomycin in Preventing Recurrent Clostridium difficile Infection in Patients Treated With Systemic Antimicrobial Agents.
Van Hise NW; Bryant AM; Hennessey EK; Crannage AJ; Khoury JA; Manian FA
Clin Infect Dis; 2016 Sep; 63(5):651-3. PubMed ID: 27318333
[TBL] [Abstract][Full Text] [Related]
3. Vancomycin Taper and Risk of Failure of Fecal Microbiota Transplantation in Patients With Recurrent Clostridium difficile Infection.
Patron RL; Hartmann CA; Allen S; Griesbach CL; Kosiorek HE; DiBaise JK; Orenstein R
Clin Infect Dis; 2017 Oct; 65(7):1214-1217. PubMed ID: 28575220
[TBL] [Abstract][Full Text] [Related]
4. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI.
Sattar A; Thommes P; Payne L; Warn P; Vickers RJ
J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749
[TBL] [Abstract][Full Text] [Related]
5. Oral teicoplanin versus oral vancomycin for the treatment of severe Clostridium difficile infection: a prospective observational study.
Popovic N; Korac M; Nesic Z; Milosevic B; Urosevic A; Jevtovic D; Mitrovic N; Markovic A; Jordovic J; Katanic N; Barac A; Milosevic I
Eur J Clin Microbiol Infect Dis; 2018 Apr; 37(4):745-754. PubMed ID: 29299697
[TBL] [Abstract][Full Text] [Related]
6. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.
Louie TJ; Emery J; Krulicki W; Byrne B; Mah M
Antimicrob Agents Chemother; 2009 Jan; 53(1):261-3. PubMed ID: 18955523
[TBL] [Abstract][Full Text] [Related]
7. Systematic Review and Meta-Analysis: Efficacy of Vancomycin Taper and Pulse Regimens in Clostridioides difficile Infection.
Sehgal K; Zandvakili I; Tariq R; Pardi DS; Khanna S
Expert Rev Anti Infect Ther; 2022 Apr; 20(4):577-583. PubMed ID: 34693838
[TBL] [Abstract][Full Text] [Related]
8. Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial.
Lee CH; Patino H; Stevens C; Rege S; Chesnel L; Louie T; Mullane KM
J Antimicrob Chemother; 2016 Oct; 71(10):2964-71. PubMed ID: 27432604
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of fidaxomicin vs oral vancomycin in recurrent Clostridium difficile infection.
Tieu JD; Williams RJ; Skrepnek GH; Gentry CA
J Clin Pharm Ther; 2019 Apr; 44(2):220-228. PubMed ID: 30350418
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Johnson S; Louie TJ; Gerding DN; Cornely OA; Chasan-Taber S; Fitts D; Gelone SP; Broom C; Davidson DM;
Clin Infect Dis; 2014 Aug; 59(3):345-54. PubMed ID: 24799326
[TBL] [Abstract][Full Text] [Related]
11. Effect of vancomycin dose on treatment outcomes in severe Clostridium difficile infection.
Lam SW; Bass SN; Neuner EA; Bauer SR
Int J Antimicrob Agents; 2013 Dec; 42(6):553-8. PubMed ID: 24103633
[TBL] [Abstract][Full Text] [Related]
12. Fidaxomicin versus vancomycin for Clostridium difficile infection.
Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection.
Gerding DN; Hecht DW; Louie T; Nord CE; Talbot GH; Cornely OA; Buitrago M; Best E; Sambol S; Osmolski JR; Kracker H; Locher HH; Charef P; Wilcox M
J Antimicrob Chemother; 2016 Jan; 71(1):213-9. PubMed ID: 26433782
[TBL] [Abstract][Full Text] [Related]
14. Comparison of oral vancomycin capsule and solution for treatment of initial episode of severe Clostridium difficile Infection.
Bass SN; Lam SW; Bauer SR; Neuner EA
J Pharm Pract; 2015 Apr; 28(2):183-8. PubMed ID: 24375999
[TBL] [Abstract][Full Text] [Related]
15. Best strategies in recurrent or persistent Clostridium difficile infection.
Cocanour CS
Surg Infect (Larchmt); 2011 Jun; 12(3):235-9. PubMed ID: 21767157
[TBL] [Abstract][Full Text] [Related]
16. Vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea.
Bishara J; Wattad M; Paul M
Clin Infect Dis; 2007 Dec; 45(12):1646-7; author reply 1649-51. PubMed ID: 18190329
[No Abstract] [Full Text] [Related]
17. Pulsed dosing and extended daily dosing of oral vancomycin do not facilitate clearance of
Pearlmutter BS; Carlisle MG; Wilson BM; Sangwan N; Donskey CJ
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0090323. PubMed ID: 38095427
[TBL] [Abstract][Full Text] [Related]
18. A pilot study to assess bacterial and toxin reduction in patients with Clostridium difficile infection given fidaxomicin or vancomycin.
Thabit AK; Alam MJ; Khaleduzzaman M; Garey KW; Nicolau DP
Ann Clin Microbiol Antimicrob; 2016 Apr; 15():22. PubMed ID: 27071986
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model.
Chilton CH; Crowther GS; Todhunter SL; Ashwin H; Longshaw CM; Karas A; Wilcox MH
J Antimicrob Chemother; 2015 Sep; 70(9):2598-607. PubMed ID: 26078392
[TBL] [Abstract][Full Text] [Related]
20. Vancomycin therapy for severe Clostridium difficile-associated diarrhea.
Huggan PJ; Murdoch DR
Clin Infect Dis; 2007 Dec; 45(12):1647-8; author reply 1649-51. PubMed ID: 18190330
[No Abstract] [Full Text] [Related]
[Next] [New Search]
